Prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire

AIDS

Volumn 17, Issue SUPPL. 3, 2003, Pages

  Adjé Touré, Christiane ^a   Celestin, Bilé ^a   Hanson, Debra ^b   Roels, Thierry H ^a,b   Hertogs, Kurt ^c   Larder, Brendan ^d   Diomande, Fabien ^a   Peeters, Martine ^e   Eholié, Serge ^f   Lackritz, Eve ^b   Chorba, Terence ^a,b   Nkengasong, John N ^a,b  

^a Project RETRO CI Abidjan   (Côte d’Ivoire)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Virco BVBA   (Belgium)

^d Virco UK Ltd   (United Kingdom)

^e INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^f Department of Clinical Microbiology   (Côte d’Ivoire)

Author keywords

Africa; Antiretroviral; Drug resistance; HIV 1; Viral load rebound

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; COTE D'IVOIRE; DRUG EFFECT; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; REBOUND; REGRESSION ANALYSIS; SEROPREVALENCE; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

EID: 0042629378     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200317003-00004     Document Type: Article

References (16)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Nkengasong J, Borget M-Y, Maurice C, Boateng E, Kalou M, Djomand G, et al. Distribution of HIV-1 plasma RNA viral load and CD4+ T-cell counts among HIV-infected Africans evaluated for antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28:99-101.
3. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, et al. Virologic and Immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS 2003; 17 (Suppl 3):S5-S15.
4. Nkengasong J, Maurice C, Koblavi S, Kalou M, Yavo D, Maran M, et al. Evaluation of HIV serial and a parallel serologic testing algorithms in Abidjan, Cote d'Ivoire. AIDS 1999; 13:109-117.
5. Nkengasong J, Maurice C, Koblavi S, Kalou M, Bile C, Yavo D. Field evaluation of a combination of monospecific ELISAs for type-specific diagnsosis of HIV-1 and HIV-2 infections in HIV-seropositive persons in Abidjan, Ivory Coast. J Clin Microbiol 1998; 36:123-127.
6. Adjé C, Cheingsong R, Roels T, Maurice C, Djomand G, Verbiest W, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr 2001; 26:501-506.
7. Stanford HIV RT and Protease sequence database. Available at http://hivdbford.edu/hiv/Notes.pl.
8. Hertogs K, de Béthune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42:269-276.
9. Pauwels R, Hertogs K, Kemp S, et al. Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis [abstract 51]. Antiviral Ther 1998; 3 (Suppl 1):35-36.
10. Cozzi-Lepri AC, Sabin CA, Staszewski S, Hertogs K, Muller A. Resistance profiles in patients with viral load rebound on potent antiretroviral therapy. J infect Dis 2000; 181:1143-1147.
11. Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000; 14:F9-F15.
12. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-366.
13. Harrigan R, Larder B. Extent of cross-resistance between agents used to treat HIV type 1 infection in clinically derived isolates. Antimircob Agents Chemother 2002; 46:909-912.
14. Witcomb JM, Paxinos EE, Huang W, Maranta M, Limoli K, Chappey C, et al. The presence of nucleoside analogue mutations (NAMs) is highly correlated with reduced susceptibility to all NRTI. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 569].
15. Pellegrin I, Izopet J, Reynes J, Denayrolles M, Montes B, Pellegrin JL, et al. Emergence of zidovudine and multidrug resistance mutations in the HIV-1 RT gene in therapy naive patients receiving stavudine plus didanosine combination therapy. AIDS 1999; 13:1705-1709.
16. Miller V, Ait-khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, et al. HIV-1 RT genotype and susceptibility to RT inhibitors during abacavir monotherpy and combination therapy. AIDS 2000; 14:163-171.